Therefore, it was hypothesized that biocompatible polymer could serve as a robust systemic delivery platform for stapled oncolytic peptides, which can induce tumor lysis and TAA release, and improve the efficacy of PD-L1 inhibitor-based immunotherapy for CRC. Here, CD274 is linked to neoplasm.